Skip to main content
Figure 1 | Journal for ImmunoTherapy of Cancer

Figure 1

From: The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

Figure 1

LBH589 in combination with an adoptive cell transfer therapy reduces tumor burden in a subcutaneous B16-F10 melanoma model. A. Treatment schedule. B. Tumor growth measurements of the mean area of tumors in control mice treated with irradiation only, LBH589 following irradiation, Pmel T cell adoptive transfer, or Pmel T cell adoptive transfer therapy with LBH589 (n = 8 mice/group). Results are representative of at least three independent experiments. Two-way ANOVA analyses were performed to determine statistical significance between treatment groups.

Back to article page